Hunter et al. 1 compared vecuronium and atracurium in patients with normal and absent renal function undergoing a variety of surgical procedures. They found no difference between the two groups in duration of action of either drug and no evidence of accumulation. Fahey et al.2 compared the pharmacokinetics of vecuronium in patients with and without renal failure and found no significant difference in duration or evidence of accumulation between the two groups. Other authors 3'4 have demonstrated that atracurium showed no evidence of accumulation or prolongation of effect in the renal failure patient. However, some studies have shown prolongation of effect ~ and evidence of cumulation 6 with vecuronium in the anephric patient.
Hunter et al. 1 compared vecuronium and atracurium in patients with normal and absent renal function undergoing a variety of surgical procedures. They found no difference between the two groups in duration of action of either drug and no evidence of accumulation. Fahey et al. 2 compared the pharmacokinetics of vecuronium in patients with and without renal failure and found no significant difference in duration or evidence of accumulation between the two groups. Other authors 3'4 have demonstrated that atracurium showed no evidence of accumulation or prolongation of effect in the renal failure patient. However, some studies have shown prolongation of effect ~ and evidence of cumulation 6 with vecuronium in the anephric patient.
Since vecuronium is a non-depolarizing relaxant which produces a neuromuscular blockade of short duration and without adverse cardiovascular effects, 2 it would seem ideal for the renal transplant patient. These patients frequently have accompanying multiple organ system disease and the procedure is one during which hypotension can have markedly adverse effects. While the muscle relaxant properties of atracurium and its lack of dependence on renal clearance for elimination make it seem useful for the transplant population, its possible histamine release with concomitant hypotension 7 could limit its use in this group. The purpose of this study is to compare the neuromuscular effects of atracurium and veeuronium in the cadaver renal transplant patient.
Methods
After Institutional Review Board approval and informed consent, 20 ASA physical status Class IlI patients CAN I ANAESTH 1989 / 36:1 I pp35-9 undergoing cadaveric renal transplantation were studied. All patients were free of uraemic neuropathy and assigned by computer generated randomization to receive either atracurium or vecaronium. Premeditation consisted of morphine sulphate 0.08mg-kg -I and glycopyrrolate 0.0l mg'kg -t up to 0.3 mg IM one hour before surgery. Induction consisted of thiopentone 4-6mg-kg -t IV followed by succinylcholine 1.0mg.kg -I to facilitate tracheal intubation. Maintenance of anaesthesia consisted of isoflurane (ET concentration of 0.5-1.0 per cent as determined by a Beckman LB-3 end tidal monitor) in 50 per cent N20/50 per cent O2 and fentanyl 4-6 Ixg" kg-t IV.
After induction and prior to succinylcholine administration, the ulnar nerve was stimulated with supramaximal 2Hz train-of-four square wave impulses (0.2 msec duration) every 10 seconds via 25-gauge subcutaneous elecrodes placed at the wrist. Supramaximal stimulus was confirmed by increasing the voltage of the nerve stimulator until no further increase of the twitch height was observed. Subsequently, the voltage was increased to 20 per cent above this value which was accepted as supramaximal. Neuromuscular function was measured continuously by recording the force of thumb adduction with a Grass polygraph (Model 7) via a Grass FTI0 force transducer (Grass Medical Instruments, Quincy, Mass. U.S.A.).
After a baseline TOF was obtained, succinylcholine was administered. Time to maximum block was recorded (SDC Max). After 90 per cent recovery of TI from succinylcholine (SDC Rec 90) either atracurium (ATR) 0.25 mg-kg-~ or vecuronium (VEC) 0.05 mg.kgwere administered and the following times were noted: time to maximum block onset (first dose Max), injection to start of recovery (Start RECI), injection to 25 per cent TI twitch recovery (REC 250, injection to 75 per cent twitch recovery (REC 75t), injection to 90 per cent twitch recovery (REC 900 and time from 25-75 per cent recovery (REC 25-751). Maximum blockade percentage (MAX block1) was also measured.
At 90 per cent Tt recovery, an identical dose of the same non-depolarizing relaxant administered intravenously if time permitted. Time from second dose to onset of maximum block (second dose Max) and 90 per cent T1 recovery (REC 902) were then measured. At the conclusion of surgery, neuromuscular blockade was reversed with neostigmine 2.5 mg and glycopyrrolate 0.5 mg. One way ANOVA was performed to determine significance between the groups. A paired t test was performed between REC 901 and REC 902 for vecuronium and atracurium, respectively, in those patients who received two doses of the relaxants. A p < 0.05 was considered 
Results
The results of the study are summarized in Tables 1, It and III. There were no significant differences between the two groups in age, weight or time from last dialysis. Preoperative serum K + ranged from 3.6mEq-L -I to 5.2 mEq. L-1. There was also no significant difference in time of onset of succinylcholine block or SDC REC 90. (Table  III) . However, examination of the data reveals Diff 90 for patients in liB (vecuronium) was much longer (25.62 -4.34 rains) than in IB (atraeurium 13.77 -+ 3.35 mins).
Discussion
Hunter et al) administered 0.5mg'kg -t boluses of atracurium to normal and anephric surgical patients and found time to beginning of neuromuscular blockade and maximum suppression longer in anephrie than normal patients while duration of block was the same. When 0.2mg.kg -~ increments were given, no evidence of accumulation was found in the normal or anephric patients. Another study 3 found no evidence of accumulation in renal failure patients receiving atracurium, while deBros et al. 4 showed no difference in pharmacokinetie or pharmacodynamic parameters between normal and anephric surgical patients receiving the drug. There seems to be ample evidence, then, that in terms of pharmaeokinetics and pharmacodynamics atracurium is an appropriate muscle relaxant for use in the renal failure patient. Vecuronium has also been described as a suitable non-depolarizing agent for the clinically or anatomically anephric patient. ~.2 Fahey et al. 2 showed no difference in onset or recovery time of vecuronium between normal and cadaver transplant patients. Another group t found no difference in duration of block or evidence of accumulation after multiple doses of vecuronium were administered to normal and anepbric patients. However, Lynam et al., s while finding no difference in onset time or time from injection to beginning of recovery, did demonstrate an increase in duration from injection to 25 per cent recovery and recovery time (25-75 per cent recovery) in cadaver transplant patients when compared with normal renal function patients receiving tb.e same bolus dose (0.1 mg'kg -l) of vecuronium. Bencini 9 found a slower onset time of vecuronium in renal patients receiving 100p, g.kg -t of veeuronium compared to normal patients.
Bevan 6 studied what effect the administration of multiple top-up doses of 10 ~,g" kg-~ of vecuronium at 10 per cent recovery of T1 might have when administered to renal failure and normal renal function patients. Renal failure patients who received more than 10 top-up doses (generally constituting a period of two hours) showed a progressive, significant increase in the duration of action of approximately 50 per cent over two hours. This evidence of accumulation was not seen in patients with normal renal function. Our study does not compare the effects of vecuronium in renal transplant patients with normal patients. However, we did contrast the effects with that of atracurium, a drug well documented to be pharmaeokinetically unaffected in the renal transplant patient. 3,4.s While we found no significant difference in any measured parameter between the two groups after a single dosage as Lynam s and Bencini 9 did, we did find evidence of accumulation after a second dose of vecuronium when compared to the effect of a second dose of atracurium. This would seem to support Bevan's evidence of accumulation in the renal failure patient as a whole. The reason for this evidence and that of Lynam and Bencini's studies is unclear.
In Lynam's study, plasma clearance of vecuronium was measured. There was no correlation between the duration of blockade and plasma clearance of vecuronium in the renal failure patient.
Fisher et al. ~~ demonstrated a cumulative effect when veeuronium was administered after initial doses varying from 30-80p, g.kg -1. When five repeated doses of 201a,g.kg -1 were administered at 25 per cent TI, the component of plasma concentration resulting from the initial dose had entered the elimination phase. This was felt to explain the cumulation seen with repeated doses of vecuronium in patients with normal renal function.
Bencini 9 measured urinary excretion of vecuronium in normal patients and found only moderate amounts of vecuronium in the urine. In rats H a maximum of 14 per cent of an injected dose of vecuronium is excreted unchanged in the urine. To determine what effect urine output might have on vecuronium clearance and accumulation in our study, we compared the REC 902 value of these patients with "low flow" urine output (n = 3) after transplant insertion (86.89 ---36.2 mins) with those (n = 2) who had normal urine flow (92.7 +-5.9 rains). There was no statistical significance between the two values but the patient population was small.
One factor that might be considered is the use of isoflurane. Isoflurane is known to effect the duration of non-depolarizing muscle relaxants including the two agents used in our study. ~2-14 Rupp et al. 13 compared the EDso of atracurium when given to patients receiving balanced anaesthesia and patients receiving 0.75 per cent end-tidal isoflurane and found the EDso to be significantly less in patients receiving isoflurane. Rupp 13 also studied the effects of isoflurane on vecuronium and found that it interacts differently with vecuronium from other non-depolarizing muscle relaxants. While enflurane and isoflurane were equipment in augmentation of nondepolarizing blocks caused by d-tubocurarine or pancuronium, isoflurane was less potent than enflurane in augmenting vecuronium. Also, increasing the concentration of these inhalational agents had less effect on neuromuscular blockade produced by vecuronium than on blockades produced by paneuronium or d-tubocurarine. In fact, there was no difference in onset or cessation of block with vecuronium when increasing end-tidal isoflurane concentration.
Rupp et al.14 calculated the EDso of vecuronium at an end-tidal isoflurane concentration of 0.7 per cent to be 14.7 p.g.kg -1. Sokoll to showed the EDso of atracurium to be 70lxg .kg -I using a 0.6-0.68 per cent end-tidal isoflurane concentration. Another study~2 demonstrated an EDso of 68 wg' kg -1 of atracurium in patients receiving 0.75 per cent end-tidal isoflurane. Our study used doses of 50 ~g" kg ~ of vecuronium and 250 lag-kg-t of atracurium. These doses represent 3.4 times the EDso ofvecuronium as shown in Rupp's J4 study and 3.57 times the EDso of atracurium as shown in Sokoll's 12 and Rupp's Is work. Considering that isoflurane seems m potentiate vecuronium less than other non-depolarizing agents and that our study utilized a proportionately slightly higher dose of atracurium than vecuronium, we do not feel that the presence of isoflurane explains the accumulation effect of vecuronium when compared to atracurium in the renal transplant patient.
This conclusion is supported by Lepage et al. 's ~5 study of veeuronium and atracurium in patients with end stage ren',d failure. An accumulative effect was found with top-off doses of vecuronium when compared with supplemental doses of atracurium and no inhalational agent was used.
Gramstad and Gjerlow ~6 studied the interaction of cyclosporin and its solvent with atracurium and vecuronium in cats. After a stable 50 per cent blockade was achieved by a constant rate of infusion of the two drugs 0.8mg.kg -1 Sandimmune (cyclosporin in cremophor and ethanol) was injected intravenously over five minutes. Sandimmune potentiated the blockade induced by vecuronium from 50.7 per cent before injection to 95.2 per cent. The median blockade induced by atracurium increased from 51.3 per cent to 72.4 per cent. In another group of cats receiving an equal amount of solvent alone, containing cremophor, an agent known to decrease the onset time of pancuronium, a vecuronium analogue, the 50 per cent vecuronium blockade increased to 78 per cent, while the atracurium blockade was unaffected. Sandimmane alone was not found to have any affect on neuromuscular t~ansmission.
Our patients all received 6 mg' kg-t or,~l Sandimmune (without cremophor) within six hours of surgery and did not receive any intravenously during the procedure. While the administration of intravenous Sandimmune during a renal transplant may be of clinical significance with regard to muscle relaxants, we do not believe it explains the apparent accumulation of vecuronium in our cadaver transplant recipients who only received oral Sandimmune.
All of our patients easily reversed at the end of the procedure with no evidence of reparalysis in either group. This is in agreement with Bevan et al., 6 as is our conclusion that vecuronium may accumulate in the renal transplant patient. However, with proper neuromuscular monitoring, the drug can still be clinica/ly useful and even beneficial in this patient population considering its marked absence of systemic and cardiovascular side effects.
